A recent study shows a surge in filings against life science companies -- a high-risk industry rife with equally large failures and successes. Some critics argue that investors unfairly blame management though they knew they were joining a risky venture. Class action lawyers disagree. Regardless, life science companies must balance the optimism needed to attract investors with carefully crafted statements that will not inspire lawsuits should the news turn bad.
Walking the Line
New York Law Journal
November 29, 2004
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.